Azelaic acid esters as novel non-opiate topical pain relievers
Introducing diethyl azelate (DEA), a promising non-opiate topical pain reliever with broad-spectrum anti-inflammatory effects, suitable for direct-to-consumer products or traditional FDA drug development pathways.
Overview
Diethyl azelate (DEA) represents a novel class of non-steroidal anti-inflammatory drugs (NSAIDs) that offer a promising alternative to opiate-based pain relief. DEA and related azelaic acid esters (AAEs) have demonstrated broad-spectrum anti-inflammatory activity in laboratory, animal, and human clinical studies. By modulating pathogen-activated molecular pattern receptors (PAMPs), DEA effectively reduces inflammation, a common driver of musculoskeletal pain, by dampening downstream immune responses. This innovative topical solution offers significant potential for addressing pain without the risks associated with opiates.
Technical specifications
Key features:
- DEA modulates PAMP receptor activity to reduce inflammation.
- Broad-spectrum anti-inflammatory effects confirmed in various test systems.
- Potential for inclusion in direct-to-consumer formulations with 4% menthol for enhanced pain relief.
- DEA is a GRAS listable molecule, facilitating smoother regulatory pathways.
Applications:
- Topical pain relief for musculoskeletal conditions.
- Suitable for patients seeking non-opiate pain management solutions.
Technology readiness level
This technology is at TRL 6, having shown efficacy in relevant environments. Two potential paths are available for further development: a direct-to-consumer product launch within 9-12 months, or progression through preclinical safety studies for FDA approval in 18-24 months.
About New Frontier Labs
New Frontier Labs is a drug discovery group focused on the development of a novel class of therapeutic agents known as Membrane Acting Immunomodulators (MAIMS). These drugs function by altering the fluidity of cellular plasma membranes to address various medical conditions. The company holds multiple United States patents for these indications, including treatments for insulin resistance, type 2 diabetes, dyslipidemia, musculoskeletal pain, inflammatory dermatoses, obesity, and complications from Brown Recluse spider bites.
The company operates as a research-driven entity that seeks to out-license its intellectual property for further development and commercialization. Recently, New Frontier Labs formed a collaborative alliance with Transcell Biologics and 20/15 Visioneers to utilize human-relevant models and AI-enabled technologies, such as Digital Animal Replacement Technology (DART), to advance their drug discovery programs. This partnership aims to bridge human therapeutic target insights with existing research data, focusing on evaluating the structure-activity relationships of their drug candidates to facilitate the development of novel, human-centric therapies.
delivered to your inbox.